ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 129 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2023. The put-call ratio across all filers is 0.22 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $10,748 | -92.0% | 10,967 | -88.7% | 0.00% | – |
Q2 2023 | $134,405 | -86.6% | 96,694 | -38.5% | 0.00% | -100.0% |
Q2 2022 | $1,000,000 | +209.6% | 157,300 | +144.0% | 0.00% | – |
Q4 2021 | $323,000 | -89.1% | 64,478 | +11.6% | 0.00% | -100.0% |
Q2 2020 | $2,965,000 | +193.0% | 57,800 | +165.6% | 0.00% | +200.0% |
Q2 2019 | $1,012,000 | -21.0% | 21,763 | -21.9% | 0.00% | -50.0% |
Q4 2018 | $1,281,000 | -85.1% | 27,853 | -85.6% | 0.00% | -81.8% |
Q3 2018 | $8,590,000 | +1955.0% | 193,600 | +1717.0% | 0.01% | +1000.0% |
Q2 2018 | $418,000 | +147.3% | 10,655 | +315.9% | 0.00% | – |
Q4 2017 | $169,000 | -99.3% | 2,562 | -99.4% | 0.00% | -100.0% |
Q3 2017 | $23,259,000 | -65.8% | 464,069 | -68.5% | 0.04% | -71.2% |
Q2 2017 | $68,088,000 | +278.1% | 1,471,238 | +188.5% | 0.13% | +256.8% |
Q1 2017 | $18,008,000 | – | 509,976 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |